Neoadjuvant Gemcitabine Plus S-1 for Resectable Pancreatic Ductal Adenocarcinoma: A Propensity Score-matched Study
Anticancer Research · 2026
DOI: 10.21873/anticanres.18364 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anticancer Research, 2026. Verfasst von Takashi Kishi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of General and Digestive Surgery, Shimane University Faculty of Medicine, Shimane, Japan. Hauptthemen laut MEDLINE: Tegafur, Oxonic Acid, Deoxycytidine, Carcinoma, Pancreatic Ductal.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General and Digestive Surgery, Shimane University Faculty of Medicine, Shimane, Japan.
- Department of Surgery, Hamada Medical Center, Shimane, Japan.
- Department of General and Digestive Surgery, Shimane University Faculty of Medicine, Shimane, Japan; mahidaka@med.shimane-u.ac.jp.
Zitieren
APA
Kishi, T., Nakamura, K., Tanaka, T., Ishitobi, K., Kaji, S., Taniura, T., Matsubara, T., Yamamoto, T., & Hidaka, M. (2026). Neoadjuvant Gemcitabine Plus S-1 for Resectable Pancreatic Ductal Adenocarcinoma: A Propensity Score-matched Study. Anticancer Research. https://doi.org/10.21873/anticanres.18364
Vancouver
Kishi T, Nakamura K, Tanaka T, Ishitobi K, Kaji S, Taniura T, et al. Neoadjuvant Gemcitabine Plus S-1 for Resectable Pancreatic Ductal Adenocarcinoma: A Propensity Score-matched Study. Anticancer Research. 2026. doi:10.21873/anticanres.18364
BibTeX
@article{Kishi2026,
author = {Kishi, Takashi and Nakamura, Kosuke and Tanaka, Takayuki and Ishitobi, Kazunari and Kaji, Shunsuke and Taniura, Takahito and Matsubara, Takeshi and Yamamoto, Tetsu and Hidaka, Masaaki},
title = {Neoadjuvant Gemcitabine Plus S-1 for Resectable Pancreatic Ductal Adenocarcinoma: A Propensity Score-matched Study},
journal = {Anticancer Research},
year = {2026},
doi = {10.21873/anticanres.18364}
}
EUVIMED